<DOC>
	<DOCNO>NCT00602693</DOCNO>
	<brief_summary>RATIONALE : Giving chemotherapy , fludarabine cyclophosphamide , total-body irradiation donor umbilical cord blood transplant help stop patient 's immune system reject donor 's stem cell . The donated stem cell may replace patient 's immune cell help destroy remain cancer cell ( graft-versus-tumor effect ) . Giving infusion donor 's T-regulatory cell transplant may decrease effect . Sometimes transplanted cell donor also make immune response body 's normal cell . However , donor immune system may also react recipient 's tissue ( graft-versus-host disease ) . PURPOSE : This phase I trial study side effect best dose donor T-regulatory cell umbilical cord blood transplant treat patient advanced hematologic cancer disorder .</brief_summary>
	<brief_title>T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant Patients With Advanced Hematologic Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose ( MTD ) umbilical cord blood ( UCB ) -derived T-regulatory ( Treg ) cell . Secondary - Estimate proportion patient detectable circulate Treg cell 0 , 1 , 3 , 7 , 14 day infusion . - Estimate risk grade II-IV III-IV acute graft versus host disease ( GVHD ) day +100 infusion Treg cell . - Estimate proportion patient sustain donor engraftment . - Estimate proportion patient double chimerism 6 month 1 year . - Determine speed cumulative incidence neutrophil recovery day 42 platelet recovery 6 month UCB transplantation . - Estimate risk chronic GVHD 1 year . - Estimate probability disease-free survival 100 day 1 year . - Estimate risk fungal viral infection 1 year - Estimate risk relapse 1 year - Characterize pattern immune cell recovery 1 year OUTLINE : This dose-escalation study umbilical cord blood ( UCB ) -derived T-regulatory ( Treg ) cell . Patients receive nonmyeloablative UCB transplantation post-transplant immunosuppression protocol UMN-2005LS036 ( without antithymocyte globulin condition regimen ) . - Nonmyeloablative conditioning UCB transplantation : Patients receive allopurinol day -7 day 0 , fludarabine phosphate intravenously ( IV ) 1 hour day -6 -2 cyclophosphamide IV 2 hour day -6 ; undergo total-body irradiation ( TBI ) day -1 ; undergo UCB transplantation day 0 . - Immunosuppression therapy : Beginning day -3 continue day +100 , patient receive sirolimus intravenously ( IV ) 8-12 mg oral load dose follow single dose 4mg/day target serum concentration 3-12 mg/mL taper day +180 . Patients also receive mycophenolate mofetil IV orally every 8 hour day -3 +30 . - Radiation therapy : total body irradiation administer Day -1 200 cGy . - UCB Treg cell infusion : Patients receive escalate dos UCB-derived CD4+ CD25+ Treg cell IV day +1 ( Day +15 dose level 5 ) maximum tolerate dose obtain . After completion study treatment , patient follow day 180 , 360 , 720 .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Allopurinol</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Ages 18 75 year old Eligible coenrolled protocol UMN2005LS036 , treatment follow advanced hematologic malignancy : Acute leukemias complete remission ( high risk CR1 subsequent CR ) ; chronic myelogenous leukemia ( except refractory blast crisis ) ; myelodysplastic syndrome severe pancytopenia complex cytogenetics , largecell lymphoma , Hodgkin 's lymphoma multiple myeloma , chronic lymphocytic leukemia/small lymphocytic lymphoma , marginal zone bcell lymphoma , follicular lymphoma , lymphoplasmacytic lymphoma , mantlecell lymphoma , prolymphocytic leukemia may eligible initial therapy . Have three partially HLA match umbilical cord blood ( UCB ) unit ( 12 unit UCB transplantation per MT200502 1 unit Treg cell infusion . ) Adequate organ function Patients expose highly immunosuppressive single agent multiagent chemotherapy within 3 month , ablative preparative regimen autologous hematopoietic stem cell transplant ( HCT ) within 1 year . Pregnancy breastfeed Current active serious infection Evidence human immunodeficiency virus ( HIV ) know HIV positive serology Patients acute leukemia morphologic relapse/persistent disease define &gt; 5 % blast &gt; = 15 % cellular bone marrow % blast blast unique morphologic marker ( e.g. , Auer rod ) associate cytogenetic marker allow morphologic relapse distinguish eligible . Chronic myelogenous leukemia refractory blast crisis . Active central nervous system malignancy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>chronic myelogenous leukemia</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>prolymphocytic leukemia</keyword>
	<keyword>advanced chronic lymphocytic leukemia</keyword>
	<keyword>small lymphocytic lymphoma</keyword>
	<keyword>B-cell lymphoma</keyword>
	<keyword>follicular lymphoma</keyword>
	<keyword>diffuse large cell lymphoma</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
	<keyword>Hodgkin lymphoma</keyword>
	<keyword>multiple myeloma</keyword>
</DOC>